Source-defined biomarker
Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE)
This exact source name has not been reconciled to a broader biomarker identity.
Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE) is a source-defined biomarker in the evidence tier "FDA qualification project". This page lists evidence by type: FDA biomarker qualification projects (1), each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA qualification project
Source-level evidence only
FDA biomarker qualification projects (1)
Shown in this order: most recent snapshot first.
| Project | DDT number | Source status | Submitter | Biomarker role |
|---|---|---|---|---|
| Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE) | DDT-BMQ-000172 | Project status: Under review | Resoundant, Inc. | Not assigned |
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and assay-provider ledger.